Robert J. Gould - 07 Apr 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Director
Signature
/s/ Curt Oltmans, as attorney-in-fact for Robert J. Gould
Issuer symbol
FULC
Transactions as of
07 Apr 2022
Transactions value $
-$91,081
Form type
4
Filing time
11 Apr 2022, 17:00:13 UTC
Previous filing
05 Apr 2022
Next filing
06 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FULC Common Stock Options Exercise $44,147 +5,631 +1.11% $7.84 512,261 07 Apr 2022 Direct F1
transaction FULC Common Stock Sale -$135,228 -5,631 -1.1% $24.02* 506,630 07 Apr 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Options Exercise $0 -5,631 -2.45% $0 224,580 07 Apr 2022 Common Stock 5,631 $7.84 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.09, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.